guttitude logo

guttitude

early access
Get Checklistguttitude Pro
← Back to atlas
fulltoplow inflation risk

Roseburia

inflammatory bowel disease

Roseburia looks like a credible signal in inflammatory bowel disease, though some caution is still warranted.

Roseburia shows a strong literature footprint in inflammatory bowel disease, with substantial central evidence and broader supporting literature.

roseburia
Credibility score
65
Human translation
3/5
Reproducibility
4/5
Novelty
2/5
Actionability
4/5
Credibility 65Human translation 3/5Reproducibility 4/5Novelty 2/5Actionability 4/5
Why this scores the way it does
  • strong central evidence base
  • dense review literature
  • substantial preclinical support
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

18 papers
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
2014
Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease.
2014
Medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
2018
Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota.
2019
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Genetic effects on the commensal microbiota in inflammatory bowel disease patients.
2019
PLoS genetics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Prebiotic fructans have greater impact on luminal microbiology and CD3+ T cells in healthy siblings than patients with Crohn's disease: A pilot study investigating the potential for primary prevention of inflammatory bowel disease.
2021
Clinical nutrition (Edinburgh, Scotland)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients.
2022
Bosnian journal of basic medical sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial.
2022
EClinicalMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera.
2022
Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota signatures in inflammatory bowel disease.
2024
United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiome and its relevance to indigenous inflammatory bowel diseases in China.
2024
Gene
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Disruptions in Inflammatory Bowel Disease: A Comparative Analysis.
2024
International journal of general medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Exploring the Predictive Value of Gut Microbiome Signatures for Therapy Intensification in Patients With Inflammatory Bowel Disease: A 10-Year Follow-up Study.
2024
Inflammatory bowel diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mathematical Modeling of Vedolizumab Treatment's Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients.
2024
Bioengineering (Basel, Switzerland)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Profiles and interactions of gut microbiome and intestinal microRNAs in pediatric Crohn's disease.
2024
mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comprehensive analysis of faecal metagenomic and serum metabolism revealed the role of gut microbes and related metabolites in detecting colorectal lateral spreading tumours.
2025
Virulence
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The intestinal mucosa-associated microbiota in IBD-associated arthritis displays lower relative abundance of Roseburia intestinalis.
2025
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota-derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4+ T cell differentiation.
2025
iMeta
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Supporting primary evidence

1 papers
Linkage analysis identifies novel genetic modifiers of microbiome traits in families with inflammatory bowel disease.
2022
Gut microbes
Human primary paper with plausible association relevance to the disease context.

Preclinical supporting evidence

10 papers
Diet rapidly and reproducibly alters the human gut microbiome.
2014
Nature
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease.
2015
Genome biology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human Gut Symbiont Roseburia hominis Promotes and Regulates Innate Immunity.
2017
Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis supernatant ameliorates colitis induced in mice by regulating the immune response.
2019
Molecular medicine reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats.
2021
Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Altered microbial biogeography in an innate model of colitis.
2022
Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Microbiome Composition Is Associated With Future Onset of Crohn's Disease in Healthy First-Degree Relatives.
2023
Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity.
2023
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis-derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses.
2024
Journal of extracellular vesicles
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Metal-Organic Framework-Remodeled Gut Microbiota Alleviates Colonic Inflammation via Selective Modulation of Roseburia intestinalis.
2025
ACS nano
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

18 papers
Manipulating the gut microbiota to maintain health and treat disease.
2015
Microbial ecology in health and disease
Relevant review or meta-analysis for the signal-disease area.
Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut.
2016
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.
2019
United European gastroenterology journal
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Profile in Pediatric Patients With Inflammatory Bowel Disease: A Systematic Review.
2021
Frontiers in pediatrics
Relevant review or meta-analysis for the signal-disease area.
Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis.
2021
Journal of clinical medicine
Relevant review or meta-analysis for the signal-disease area.
Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species.
2021
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Features of Gut Microbiome Associated With Responses to Fecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review.
2022
Frontiers in medicine
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023
Digestion
Relevant review or meta-analysis for the signal-disease area.
Anaerobes in specific infectious and noninfectious diseases: new developments.
2023
Anaerobe
Relevant review or meta-analysis for the signal-disease area.
Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.
2024
International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota mediated T cells regulation and autoimmune diseases.
2024
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Comparative analysis of Parkinson's and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion.
2025
NPJ Parkinson's disease
Relevant review or meta-analysis for the signal-disease area.
From traditional to artificial intelligence-driven approaches: Revolutionizing personalized and precision nutrition in inflammatory bowel disease.
2025
Clinical nutrition ESPEN
Relevant review or meta-analysis for the signal-disease area.
Interplay of Gut Microbiota, Biologic Agents, and Postoperative Anastomotic Leakage in Inflammatory Bowel Disease: A Narrative Review.
2025
International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease.
2025
Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Changes in Metabolic Dysfunction-Associated Steatohepatitis and Inflammatory Bowel Disease: Common Pathogenic Features.
2025
Current issues in molecular biology
Relevant review or meta-analysis for the signal-disease area.
Is the microbiome the answer to inflammatory bowel disease: systematic review.
2025
Langenbeck's archives of surgery
Relevant review or meta-analysis for the signal-disease area.
Diet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective.
2026
Pharmaceuticals (Basel, Switzerland)
Relevant review or meta-analysis for the signal-disease area.